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Generalized vitiligo is a common autoimmune disease in which acquired patchy depigmentation of skin, hair, and
mucous membranes results from loss of melanocytes from involved areas. Previous genetic analyses have focused
on vitiligo susceptibility, and have identified a number of genes involved in disease risk. Age of onset of
generalized vitiligo also involves a substantial genetic component, but has not previously been studied
systematically. In this study, we report a genome-wide association study of vitiligo age of onset in 1,339
generalized vitiligo patients, with replication in an independent cohort of 677 cases. We identified a quantitative
trait locus for vitiligo age of onset in the major histocompatibility complex (MHC) class II region, located near
c6orf10-BTNL2 (rs7758128; P¼ 8.14 1011), a region that is also associated with generalized vitiligo susceptibility.
In contrast, there was no association of vitiligo age of onset with any other MHC or non-MHC loci that are
associated with vitiligo susceptibility. These findings highlight the differing roles played by genes involved in
vitiligo susceptibility versus vitiligo age of onset, and illustrate that genome-wide analyses can be used to identify
genes involved in quantitative aspects of disease natural history, as well as disease susceptibility per se.
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INTRODUCTION
Generalized vitiligo is a common autoimmune disease in which
acquired patchy depigmentation of skin, hair, and mucous
membranes results from loss of melanocytes from involved
areas (Rezaei et al., 2006). Moreover, generalized vitiligo is
epidemiologically associated with increased risk of several other
autoimmune diseases, both in patients and their close relatives
(Alkhateeb et al., 2003; Laberge et al., 2005), suggesting that
these autoimmune diseases involve shared susceptibility genes.
Twin and epidemiological studies indicate that generalized
vitiligo is a complex disease involving multiple genetic and
environmental susceptibility factors, and genetic linkage,
candidate gene, and recent genome-wide association studies
have implicated a number of genes in vitiligo susceptibility
(Spritz, 2008; Jin et al., 2010a, b; Quan et al., 2010; Birlea et al.,
2011). Most of these genes encode immunoregulatory proteins,
and many have also been implicated in susceptibility to some of
the other autoimmune diseases that are epidemiologically
associated with generalized vitiligo.
In addition to vitiligo susceptibility per se, variation in
vitiligo age of onset also involves a genetic component.
Vitiligo age of onset is correlated among affected relatives
(Majumder et al., 1993), and mean age of onset is
significantly earlier in multiplex families (21.5±15.0 years)
than among sporadic cases (24.2±16.2 years) (Laberge et al.,
2005). Furthermore, patients with early disease onset tend to
have more affected relatives and more extensive disease
involvement (Laberge et al., 2005). In this study, using
MENDEL 7.0 (Lange et al., 2001), we calculated heritability
of vitiligo age of onset as 0.45 in 184 multiplex families.
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We previously described a genome-wide association study
of generalized vitiligo susceptibility in whites of European
descent, in which we identified a number of loci that
contribute to disease susceptibility (Jin et al., 2010a, b; Birlea
et al., 2011). These included major association signals in
the major histocompatibility complex (MHC) class I and
class II regions and at least 11 non-MHC loci. Here, we have
specifically addressed vitiligo age of onset as a heritable trait
distinct from disease susceptibility per se, re-analyzing
our previous genome-wide data set by coding patients’ self-
reported age of disease onset as a quantitative trait, testing for
association genome-wide, and then re-testing significant
association signals in an independent replication cohort.
These analyses identified a quantitative trait locus in the
MHC class II region that contributes significantly to general-
ized vitiligo age of onset, thus illustrating that genome-wide
analyses can be used to identify genes involved in
quantitative aspects of disease natural history, as well as
disease susceptibility.
RESULTS
Genome-wide scan
Considering all 2,016 cases in the present study, the mean
vitiligo age-of-onset was 24.45 years; 24.84 for males (634
cases) and 24.27 for females (1,382 cases) (Table 1). After
excluding some cases and markers by applying stringent
quality control filters (Jin et al., 2010a), we tested association
of 520,460 autosomal and X-chromosomal single-nucleotide
polymorphisms (SNPs) with generalized vitiligo age of onset
in 1,339 unrelated cases (Table 1) (Jin et al., 2010a) by
linear regression, considering Po5108 as the criterion for
genome-wide significance (Ioannidis et al., 2009). A quanti-
le–quantile plot of the genome-wide P-values (Figure 1)
generally fit the null expectation, except at the extreme of
the tail where observed P-values departed from expectation.
The overall genomic inflation factor (Bacanu et al., 2002) was
1.007, indicating minimal inflation of the genome-wide
statistics because of population stratification.
As shown in Figure 1 and Supplementary Table S1 online,
the five top-ranked SNPs genome-wide (based on P-values)
were all located at chromosome 6p21.3 in the MHC class II
region. SNP rs7758128, located near c6orf10-BTNL2,
exceeded the criterion for genome-wide significance
(P¼5.98109), and three nearby SNPs showed suggestive
association: rs28362680 (P¼ 1.48106), rs28362683
(P¼1.09107), and rs10947262 (P¼ 1.48106). One
additional MHC class II region SNP, rs532098, located
4200 kb distal to the others, in the vicinity of HLA-DRB1-
DQA1, also showed suggestive evidence of association
(P¼2.03 106).
To more accurately assess the influence of these five SNPs
on vitiligo age of onset, we applied Cox proportional hazards
models (Cox, 1972) to test the multiplicative effect of each
SNP on the hazard. As shown in Supplementary Table S1
online, Cox models yielded results very similar to the
genome-wide linear regression results, with P-values of
6.24109, 1.44 106, 9.82 108, 1.44106, and
5.12106 for SNPs rs7758128, rs28362680, rs28362683,
rs10947262, and rs532098, respectively.
As shown in Figure 2a, these five SNPs derive from a
prominent association peak for generalized vitiligo age of
onset in the MHC class II region, which corresponds closely
to a highly significant association peak for generalized vitiligo
susceptibility (Figure 2b, and Jin et al., 2010a). In contrast,
Table 1. Summary description of the patients with generalized vitiligo used in this study
Generalized vitiligo age of onset
Study cohort No. of patients Mean SD Female (%) Occurrence of other autoimmune diseases (%)1
Genome-wide scan 1,339 24.06 16.40 70.20 31.29
Replication cohort 677 25.23 15.73 65.29 31.31
1Includes autoimmune thyroid disease, rheumatoid arthritis, psoriasis, adult-onset autoimmune diabetes, pernicious anemia, Addison’s disease, and systemic
lupus erythematosus, which are the principal autoimmune diseases that are epidemiologically associated with generalized vitiligo (Alkhateeb et al., 2003;
Laberge et al., 2005).
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Figure 1. Genome-wide association results for generalized vitiligo age of
onset. The genome-wide distribution of log10(P-values) from the unadjusted
linear regression analysis for 520,460 polymorphic single-nucleotide
polymorphisms (SNPs) that passed quality control (QC) filters in 1,339
unrelated generalized vitiligo patients is shown plotted across the
chromosomes. The dotted line indicates the genome-wide significance
criterion (Po5108). The inset shows quantilequantile (QQ) plots of the
observed versus expected log10(P-values) for unadjusted linear regression
statistics. The plot in red shows P-values for all 520,460 SNPs, whereas the
plot in blue shows P-values excluding the 3,400 SNPs located across the
extended major histocompatibility complex (MHC; chromosome 6:
25.9–33.4Mb, genome build GRCh37).
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there was no association signal for vitiligo age of onset in the
MHC class I region that is similarly strongly associated with
vitiligo susceptibility (Jin et al., 2010a), indicating that the
MHC class II region has a specific influence on vitiligo age of
onset, whereas the class I region does not.
The SNPs rs7758128, rs28362680, rs28362683, and
rs10947262 span 37.8 kb within one block of strong linkage
disequilibrium, whereas rs532098, over 200 kb distal, is not
in linkage disequilibrium with the other four SNPs (Supple-
mentary Figure S1 online). To determine which of these five
SNPs exert independent effects on the age of onset, and to
test whether family history of vitiligo, co-occurrence of other
concomitant autoimmune disorders, and gender might
also contribute to vitiligo age of onset, we included these
eight variables in a Cox model, utilizing L1 penalized (lasso)
estimation and a small L2 penalty (Goeman, 2010) to identify
variables with the strongest effects on the age of onset. Under
the optimal value of l1¼5.04 and l2¼0.01, three variables
(SNP rs7758128, SNP rs532098, and family history) showed
non-zero coefficients. Accordingly, we re-tested association
of rs7758128 and rs532098 with the age of onset in both
linear regression analysis and in a Cox model adjusted for
family history. As shown in Table 2, incorporating family
history as a covariate slightly improved the linear regression
and the Cox model P-values for rs7758128, P¼3.22 109
and P¼4.92 109, respectively, whereas for rs532098 the
P-values were slightly worse, P¼1.56 105 and P¼1.30
105, respectively. Together, these results indicate that SNPs
rs7758128 and rs532098 may exert independent effects on
vitiligo age of onset, and may partially explain the previously
observed association between vitiligo age of onset and
positive family history (Laberge et al., 2005).
Replication analysis
To test the replication of association of rs7758128 and
rs532098 with vitiligo age of onset, we genotyped these two
SNPs in an independent cohort of 677 European-derived
white generalized vitiligo patients (Table 1) (Jin et al., 2010a).
As shown in Table 2, for rs7758128 we confirmed association
with vitiligo age of onset in the replication cohort (linear
regression P¼2.05 103; Cox model P¼ 0.014). Further-
more, the meta-analysis of rs7758128 in the genome-wide
and replication data sets yielded highly significant P-values
(linear regression P¼8.14 1011; Cox model P¼1.36
109), with a hazard ratio of 1.50 per A allele. For rs532098,
we observed the same effect direction in the replica-
tion cohort, although the P-values were only marginal
(linear regression P¼0.081; Cox model P¼0.044) and
the combined P-values did not achieve genome-wide
significance (linear regression P¼ 1.83105; Cox model
P¼4.23 106).
DISCUSSION
Our findings show that variation in the MHC class II region,
best represented by rs7758128 in the vicinity of BTNL2, is
strongly associated with generalized vitiligo age of onset.
In contrast, other loci that are associated with generalized
vitiligo susceptibility (Jin et al., 2010a, b; Birlea et al., 2011),
including variation in the MHC class I region, are not
associated with disease age of onset (Supplementary Table S2
online). These findings thus indicate that different loci
have differing roles in vitiligo susceptibility versus vitiligo
age of onset.
Penalized regression analysis suggested that MHC class II
SNPs rs7758128 and rs532098 may contribute independently to
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Figure 2. Major histocompatibility complex association results from
genome-wide analyses of generalized vitiligo age of onset and susceptibility.
(a) Results of association analyses of the 3,400 (black dots) MHC region
(chromosome 6: 25.9–33.4Mb, genome build GRCh37) single-nucleotide
polymorphisms (SNPs) with generalized vitiligo age of onset in 1,339
unrelated patients. The five top-ranked SNPs genome-wide are represented by
red dots (dots representing rs28362680 and rs10947262 are too close to
resolve). (b) Results of association analyses of the 3,400 (black dots) MHC
region SNPs with generalized vitiligo susceptibility in 1,392 unrelated
patients versus 2,629 unrelated controls (Jin et al., 2010a) using
Cochran–Armitage trend tests implemented in PLINK (Purcell et al., 2007).
The five top-ranked SNPs from the age of onset analysis are represented by red
dots (dots representing rs28362680, rs28362683, and rs10947262 are too
close to resolve). (c) A genomic map of the five top-ranked age-of-onset-
associated SNPs genome-wide. The arrows indicate gene orientations.
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vitiligo age of onset, although replication of rs532098 association
with vitiligo age of onset was only marginally significant. Linear
regression analyses indicated that rs7758128 accounts for 2.5%
of the variance of vitiligo age of onset, rs532098 accounts for
1.5%, and both SNPs together account for 3.4% of the variance
of vitiligo age of onset. The early age-of-onset-associated alleles
of these two SNPs are also associated with increased disease
susceptibility (Jin et al., 2010a), and the associated allele of
rs532098 is in strong linkage disequilibrium with HLA-DR4,
which we previously showed is associated with both vitiligo
susceptibility and early disease onset (Fain et al., 2005).
To determine which HLA class II haplotypes include the SNP
alleles that affect vitiligo age of onset, we analyzed class II alleles
and SNP data from 74 previously reported vitiligo trios (Fain
et al., 2005) and 37 CEPH (Centre d’Etude du Polymorphisme
Humain) trios (Bugawan et al., 2000). This analysis showed that
the A allele of rs7758128 that is associated with earlier vitiligo
age of onset is exclusively located on the HLA class II haplotype
DRB1*1301-DQA1*0103-DQB1*0603, although the majority
of this haplotype (0.61) carry the C allele.
As shown in Figure 2c, the 27-kb rs7758128/rs28362680/
rs28362683/rs10947262 SNP cluster that is associated with
vitiligo age of onset is located in close proximity to only one
known gene, BTNL2, which encodes an immunoglobulin
superfamily membrane protein implicated in T-cell activa-
tion, and one predicted gene of unknown function, c6orf10.
The c6orf10/BTNL2 gene region has been associated with
susceptibility to many other autoimmune diseases, including
type 1 diabetes (Orozco et al., 2005; He et al., 2009),
rheumatoid arthritis (Orozco et al., 2005; Cui et al., 2009),
systemic lupus erythematosus (Orozco et al., 2005), ulcera-
tive colitis (Pathan et al., 2009), psoriasis (Feng et al., 2009),
and Graves’ disease (Simmonds et al., 2006), as well as with
sarcoidosis (Valentonyte et al., 2005).
Biological evidence indicates that variation in the HLA
class I region (specifically, HLA-A*0201) may contribute to
disease susceptibility by mediating ongoing immune surveil-
lance against malignant melanomas (and thus recognition of
melanocytes) by the immune system (Spritz, 2010; Jin et al.,
2010a). In contrast, association of the MHC class II region
with both disease susceptibility and disease age of onset
suggests that variation in this region might mediate response
to environmental triggers encountered over the course of the
life of genetically susceptible individuals.
SUBJECTS AND METHODS
Subjects
The discovery cohort comprised 1,339 unrelated generalized
vitiligo patients and the replication cohort 677 additional
unrelated patients, all of European white origin (Jin et al.,
2010a). The age of onset was by self-report. All study
participants provided written informed consent, and the study
was approved by each institutional review board and was
conducted according to the Declaration of Helsinki Principles.
Genotyping and quality control
DNA preparation, genome-wide genotyping using the Illumina
610-Quad BeadChip (Illumina, San Diego, CA) and replication
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genotyping using the Sequnom MassArray iPLEX system
(Sequenom, San Diego, CA), and quality control filtering of
the data have been described previously (Jin et al., 2010a).
Statistical analyses
For both the genome-wide and replication analyses, linear
regression analyses were performed using PLINK (Purcell et al.,
2007), considering the age of onset as a quantitative trait. To
control for population stratification, we performed principal
component analysis in the 1,339 discovery phase cases using
EIGENSOFT (Price et al., 2006), using a subset of 21,642
independent SNPs, and included the three significant principal
components (Tracy–Widom Po0.1) detected as continuous
covariates in the linear regression analyses. We applied a Cox
proportional hazards model (Cox, 1972) to the five top-ranked
SNPs from the genome-wide scan and the two SNPs in the
replication analysis using STATA 10 (www.stata.com). To
obtain combined linear regression P-values, we performed
meta-analysis using the inverse variance-weighted method
(de Bakker et al., 2008). To obtain combined Cox model
P-values, we specified genome-wide scan and replication data
as different strata in the Cox model. We used L1 penalized
(lasso) estimation with a small L2 penalty in a Cox proporational
hazards model to determine those variables exhibiting the
strongest effects on age-of-onset, using cross-validation to
calculate the global optimal value of the tuning parameter l
(Goeman, 2010).
PHASE (Stephens et al., 2001), version 2.1.1, was used to
determine which HLA class II haplotypes include the SNP alleles
that affect vitiligo age of onset. Linkage disequilibrium was
calculated using Haploview (Barrett et al., 2005) version 4.1.
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